Experimental study on the efficacy of combinations of glycopeptides and β-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 4, 2005, Pages 709-716

  Domenech, Alejandro ^a   Ribes, Sandra ^a   Cabellos, Carmen ^a   Taberner, Ferran ^a   Tubau, Fe ^a   Domínguez, M Angeles ^a   Montero, Abelardo ^a   Liñares, Josefina ^a   Ariza, Javier ^a   Gudiol, Francesc ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Animal models; GISA; Heterogeneous resistance; Vancomycin

Indexed keywords

BETA LACTAM; CEFOTAXIME; CLOXACILLIN; GLYCOPEPTIDE; PLACEBO; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLYCOPEPTIDES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PERITONITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 27144539453     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki294     Document Type: Article

References (32)

1. Ariza J, Pujol M, Cabo J et al. Vancomycin in surgical infections due to methicillin-resistant S. aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587-8.
2. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 813-5.
3. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48: 1165-7.
4. Geisel R, Schmitz FJ, Thomas L et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 1999; 43: 846-8.
5. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
6. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant S. aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-46.
7. Kim MN, Pai CH, Woo JH et al. Vancomycin intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38: 3879-81.
8. McManus J. Vancomycin resistant staphylococcus reported in Hong Kong. BMJ 1999; 318: 626.
9. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-6.
10. Ploy MC, Grelaud C, Martin C et al. First clinical isolate of vancomycin-intermediate S. aureus in a French hospital. Lancet 1998; 351: 1212.
11. Rotun SS, McMath V, Schoonmaker DJ et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteraemia. Emerg Infect Dis 1999; 5: 147-9.
12. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engld Med 1999; 340: 493-501.
13. Climo WM, Patron RL, Archer GL. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999; 43: 1747-53.
14. Domenech A, Ribes S, Cabellos C et al. A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections. Microb Drug Resist 2004; 10: 346-53.
15. Barr JG, Smyth ET, Hogg GM. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against S. aureus and S. epidermidis. Eur J Clin Microbiol Infect Dis 1990; 9: 804-9.
16. Sieradzki K, Roberts RB, Haber SW et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-23.
17. Sieradzki K, Tomasz A. Suppression of β-lactam antibiotic resistance in a methicillin-resistant S. aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother 1997; 39 Suppl A: 47-51.
18. Sieradzki K, Tomasz A.. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of S. aureus. J Bacteriol 1997; 179: 2557-66.
19. Domaracki BE, Evans AM, Venezia RA. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother2000; 44: 1394-6.
20. Hanaki H, Hiramatsu K. Combination effect of teicoplanin and various antibiotics against hetero-VRSA and VRSA. Kansenshogaku Zasshi [Japanese] 1999; 73: 1048-53.
21. Howe RA, Wootton M, Bennett PM et al. Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility. J Clin Microbiol 1999; 37: 3068-71.
22. Lozniewski A, Lion C, Mory F et al. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother 2001; 47: 83-6.
23. Seibert G, Isert D, Klesel N et al. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob Chemother 1992; 29 Suppl A: 25-30.
24. Aritaka N, Hanaki H, Cui L et al. Combination effect of vancomycin and β-lactams against S. aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother 2001; 45: 1292-4.
25. Goldstein FW, Atoui R, Ben Ali A et al. False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods. Clin Microbiol Infect 2004; 10: 342-5.
26. Haraga I, Nomura S, Nagayama A. The effects of vancomycin and β-lactam antibiotics on vancomycin-resistant Staphylococcus aureus. N Engl J Med 1999; 341: 1624.
27. National Committee for Clinical and Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA, 2000.
28. National Committee for Clinical and Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents-Tentative Guideline: NCCLS Document M26-T. NCCLS, Villanova, PA, USA, 1992.
29. Frimodt-Moller N. The mouse peritonitis model: Present and future use. J Antimicrob Chemother 1993; 31 Suppl D: 55-60.
30. Knudsen JD, Frimodt-Moller N, Espersen F. Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob Agents Chemother 1995; 39: 1253-8.
31. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
32. Mouton JW, van Ogtrop ML, Andes D et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999; 43: 2473-8.